Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Gastroenteropancreatic Neuroendocrine Tumor”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Testing effectiveness (Phase 2)Looking for participantsNCT05048901
What this trial is testing

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan 49
Early research (Phase 1)Active Not RecruitingNCT03833700
What this trial is testing

E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Who this might be right for
Solid NeoplasmsColorectal NeoplasmsGastrointestinal Tumors
Eisai Co., Ltd. 70
Large-scale testing (Phase 3)Looking for participantsNCT06937905
What this trial is testing

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 129
Not applicableStudy completedNCT05255133
What this trial is testing

Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

Who this might be right for
Neuroendocrine Tumors
Universiteit Antwerpen 22
Testing effectiveness (Phase 2)Study completedNCT02575300
What this trial is testing

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Who this might be right for
Carcinoid TumorsPancreatic NET
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT00454363
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Who this might be right for
Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1+8 more
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Study completedNCT02248012
What this trial is testing

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Who this might be right for
Neuroendocrine Carcinoma
Haukeland University Hospital 38
Testing effectiveness (Phase 2)WithdrawnNCT05582031
What this trial is testing

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Who this might be right for
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more
Translational Research in Oncology
Large-scale testing (Phase 3)Looking for participantsNCT05477576
What this trial is testing

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more
RayzeBio, Inc. 338
Testing effectiveness (Phase 2)UnknownNCT04029428
What this trial is testing

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Not applicableStudy completedNCT04696042
What this trial is testing

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Asan Medical Center 71
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Not applicableActive Not RecruitingNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Looking for participantsNCT06840821
What this trial is testing

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Who this might be right for
Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd 156
Early research (Phase 1)Study completedNCT01204476
What this trial is testing

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Who this might be right for
Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1+12 more
National Cancer Institute (NCI) 27
Large-scale testing (Phase 3)Active Not RecruitingNCT03375320
What this trial is testing

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Who this might be right for
Functioning Pancreatic Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine Neoplasm+25 more
National Cancer Institute (NCI) 298
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Testing effectiveness (Phase 2)Study completedNCT03095274
What this trial is testing

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Neoplasm of Lung
Grupo Espanol de Tumores Neuroendocrinos 126
Load More Results